Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
59.82 ^USD	-5.94%		-5.45%	-9.90%

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI

Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care

Published on 02/09/2026 at 12:27 am GMT

S&P Capital IQ

ARROWHEAD PHARMACEUTICALS, INC.

-5.94%

Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care (Sector)

Latest news about Arrowhead Pharmaceuticals, Inc.

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 - Biotechnology	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600	CI
02-06	Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-04	Ciena Set to Join S&P500	MT
01-27	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	CI
01-27	Arrowhead Pharmaceuticals Doses First Subject in Clinical Trial of Treatment for Mixed Hyperlipidemia	MT

Chart Arrowhead Pharmaceuticals, Inc.

Duration

Period

ARWR: Dynamic Chart

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

711

Sector

Biotechnology & Medical Research

More about the company